THE RESULTS OF OPEN, MONOCENTER, NONRANDOMIZED, OBSERVATION STUDY WITHOUT CONTROL GROUP TO ASSESS EFFICACY AND SAFETY OF ETANERCEPT TREATMENT IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS LITERATURE REVIEWS

E.I. Alexeeva; Т.М. Bzarova

THE RESULTS OF OPEN, MONOCENTER, NONRANDOMIZED, OBSERVATION STUDY WITHOUT CONTROL GROUP TO ASSESS EFFICACY AND SAFETY OF ETANERCEPT TREATMENT IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS LITERATURE REVIEWS

E.I. Alexeeva, Т.М. Bzarova

Abstract

The study objective was to assess efficacy and safety of etanercept treatment in combination with methotrexate in 25 patients with juvenile idiopathic arthritis. In this study were included 25 children with poly- and oligoarticulate variants of juvenile idiopathic arthritis aged 8 (6; 11) years. In the beginning of the study 17 patients had poliarticulate variant, 8 children — oligoarticulate. High clinical activity of the disease was accompanied by general inflammatory reaction. Analysis of the results has shown that etarnecept treatment ensured statistically significant and trustworthy positive dynamics of clinical and laboratory indices of disease activity. After 6 month of treatment 59% (13 from 22) of patients were diagnosed with inactive disease, after 12 months — 86% (19 from 22) of patients had this status. Etanercept treatment was well tolerated and the majority of side effects were minor or medium, reversible and caused no interruption of the treatment.
Key words: juvenile idiopathic arthritis, etanercept, metotrexate, life quality, efficacy, safety.
(Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (5): 24–31.)

About the Authors

E.I. Alexeeva

Scientific Center of Children’s Health RAMS, Moscow Sechenov First Moscow State Medical University

Т.М. Bzarova

Scientific Center of Children’s Health RAMS, Moscow

References

1. Cassidy J.T., Petty R.E., Laxer R.M., Lindsley C.B. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier. 2010. 794 p.

2. Баранов А.А. Педиатрия. Клинические рекомендации. М.: ГЭОТАР–Медиа. 2009. 387–420.

3. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников. Под общей ред. А.А. Баранова. М. 2007. 325–339.

4. Алексеева Е.И., Шахбазян И.Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. Серия: Аутоиммунные заболевания, № 5. М. 2002. 127 с.

5. Szer I.S., Kimura Y., Malleson P.N., Southwood T.R. Arthritis in children and Adolescents. Juvenile Idiopathic Arthritis. Oxford: University Press. 2006. 456 p.

6. Horneff G., Augustin S. Medical treatment of juvenile idiopathic arthritis. Med. Monatsschr. Pharm. 2008; 31: 326–336.

7. Hashkes P.J., Laxer R.M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294: 1671–1684.

8. El-Gabalawy H.S., Lipsky P.E. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2004; 4 (Suppl. 2): 297–301.

9. Foster H.E., Marshall N., Myers A. et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003; 48: 767–775.

10. Strand V., Singh J.A. Improved health related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am. J. Manag. Care. 2008; 14 (4): 234–254.

11. Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Терапевтический архив. 2007; 5: 5–8.

12. Minden K., Niewerth M., Listing J. et al. Long-term outcome in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2392–2401.

13. Алексеева Е.И., Валиева С.И, Денисова Р.В. Перспективы применения растворимых рецепторов к ФНО–α в терапии ювенильных артритов. Вопросы современной педиатрии. 2008; 7 (5): 51–57.

14. Horneff G., Schmeling H., Biedermann T. et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum. Dis. 2004; 63 (12): 1638–1644.

15. Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum. Dis. 2009; 68 (4):5 19–25.

16. Giannini E.H., Ilowite N.T., Lovell D.J. et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60 (9): 2794–2804.

17. Prince F.H.M., Twilt M., ten Cate R. et al. Long term follow up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum. Dis. 2008 [published online 15 Apr 2008 doi:10.1136/ard.2007.087411].

18. Hayward K., Wallace C. Recent developments in antirheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthr. Res. Ther. 2009, 11: 216 [doi:10.1186/ar2619].

19. Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children’s autoimmune disorders: efficacy and safety. Eur. J. Pediatr. 2011; 170: 157.

20. Pain C., McCann L. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics: Targets & Therapy. 2009; 3: 127–139.

21. Никишина И.П. Этанерцепт в лечении ювенильного артрита: от опыта клинических исследований до клинической практики. Русский медицинский журнал. 2010; 27: 1686.

22. Otten M., Prince F., Twilt M. et al. Delaed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J. Rheumatol. 2010; 37: 665–667.

23. Lovell D.J., Giannini E.H., Reiff A. et al. Long term efficacy and safety of etanercept in children with polyarticular course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open label, extended treatment trial. Arthritis Rheum. 2003; 48: 218–226.

24. Lovell D.J., Reiff A., Jones O.Y. et al. Long-term safety and efficacy of etanercept in children with polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum. 2006; 54: 1987–1994.

25. Lovell D.J., Reiff A., Ilowite N.T. et al. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with Juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.

26. Lovell D.J., Giannini E.H., Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N. Engl. J. Med. 2000; 342 (11): 763–769.

27. Kietz D.A., Pepmueller P.H., Moore T.L. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J. Rheumatol. 2001; 28: 360–362.

28. Nielsen S., Ruperto N., Gerloni V. et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2008; 26 (4): 688–692.

Review

For citations:

Alexeeva E., Bzarova Т. THE RESULTS OF OPEN, MONOCENTER, NONRANDOMIZED, OBSERVATION STUDY WITHOUT CONTROL GROUP TO ASSESS EFFICACY AND SAFETY OF ETANERCEPT TREATMENT IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS LITERATURE REVIEWS. Current Pediatrics. 2011;10(5):24-31.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Current Pediatrics

THE RESULTS OF OPEN, MONOCENTER, NONRANDOMIZED, OBSERVATION STUDY WITHOUT CONTROL GROUP TO ASSESS EFFICACY AND SAFETY OF ETANERCEPT TREATMENT IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS LITERATURE REVIEWS

Abstract

About the Authors

References

Review

For citations:

Cookies policy